In vivo antioxidants, chemical characterization and biochemical and medicinal potential of Murraya koenigii in cisplatin-induced nephrotoxicity

Abstract

Murraya koenigii (Mk) is an old plant with a significant therapeutic value throughout Africa, Asia, and Latin America. The excessive use of cisplatin (Cis> 50 mg/m²) is associated with nephrotoxicity, ototoxicity, gastrotoxicity, myelosuppression, and allergic reactions. Remedial measures are needed for the protection of nephrotoxicity against cisplatin. Thus, we have investigated Mk leaf extract’s nephroprotective effects to prevent cisplatin-induced nephrotoxicity in Wistar albino rats. The presence of polyphenols, phenolic compounds, tannins, and saponins was revealed during phytochemical investigation, and antioxidant activity was recorded. There were no toxicological symptoms in the treated rats, and no anatomical, physiological, or histological abnormalities were found compared to the control rats. The results of correcting cisplatin-induced nephrotoxicity revealed that the extract has a significant ability to treat kidney damage, with most parameters returning to normal after only three weeks of therapy. It was concluded that co-administered cisplatin with Mk leaves extract showed exceptional nephroprotective effects at a 400 mg/kg dose ratein Cis-induced nephrotoxicity.

Keywords:

• Murraya koenigii
• nephrotoxicity
• reactive oxygen species
• cisplatin
• antioxidants

Acknowledgments

Hereby, we extend our gratitude to the laboratory staff and the animal house of Bahauddin Zakariya University, Multan, Pakistan, for their cooperation throughout the study. We are grateful to the Department of Pharmacology, Faculty of Pharmacy and Alternative Medicine, Bahauddin Zakariya University, Multan, Pakistan, for providing research facilities.

Institutional review board statement

The study was conducted according to the guidelines of the National Institute of Health, 2005, and The Ethical Board of Bahauddin Zakariya University, Multan, approved the study (BZU/06-18/34547).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author received no funding from any funding agency.